News | June 03, 2022
Evonik to build new lipid production facility for mRNA-based therapies in U.S.
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
By 2025, Cipla plans to achieve carbon and water neutrality, zero-waste to landfill, anti-microbial resistance stewardship and green chemistry.
This agreement is in addition to the $92 million filling line expansion announced in November 2021
Bempedoic acid helps lower cardiovascular risk in high or very high-risk atherosclerotic cardiovascular disease (ASCVD) patients as an add-on therapy to maximally tolerated statin and/or ezetimibe
By 2025, the company plans to achieve carbon and water neutrality, zero-waste to landfill, anti-microbial resistance stewardship and green chemistry
The company will invest approximately €440 million to increase membrane manufacturing capacity in Carrigtwohill and to build a new manufacturing facility at Blarney Business Park, both in Cork, Ireland
The Portal BioRRAP will cater to all those seeking regulatory approval for biological research
Phase I trial in Rwanda and South Africa aims to evaluate mRNA HIV vaccine antigen for safety and immunogenicity and strengthen regional scientific capacity
India has the second-largest number of adults with diabetes globally, after China
Company will expand the existing production site in Wuxi to significantly increase biopharma single-use assemblies and custom design capabilities
Subscribe To Our Newsletter & Stay Updated
